Dexmedetomidine
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Conscious Sedation
Conditions
Conscious Sedation
Trial Timeline
Oct 1, 2005 → Jul 1, 2006
NCT ID
NCT00226785About Dexmedetomidine
Dexmedetomidine is a phase 3 stage product being developed by Orion Corporation for Conscious Sedation. The current trial status is terminated. This product is registered under clinical trial identifier NCT00226785. Target conditions include Conscious Sedation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03813277 | Approved | Completed |
| NCT02252523 | Phase 2 | UNKNOWN |
| NCT01266252 | Phase 3 | Completed |
| NCT00747721 | Phase 1 | Completed |
| NCT00226785 | Phase 3 | Terminated |
Competing Products
2 competing products in Conscious Sedation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AQUAVAN® (fospropofol disodium) Injection + Midazolam HCI | Eisai | Phase 3 | 77 |
| Dexmedetomidine + Propofol | Pfizer | Approved | 84 |